Safety, tolerability and weight reduction findings of oral amycretin: a novel amylin and glucagon-like peptide-1 receptor co-agonist, in a first-in-human study

被引：0
|
作者：
Gasiorek, A. [1 ]
Heydorn, A. [1 ]
Kirkeby, K. [1 ]
Key, C. [2 ]
Toubro, S. [1 ]
Schefe, L. H. [1 ]
Dahl, K. [1 ]
Hjerpsted, J. B. [1 ]
Vegge, A. [1 ]
机构：
[1] Novo Nordisk AS, Malov, Denmark
[2] ICON Plc, San Antonio Clin Res Unit, San Antonio, TX USA
来源：
DIABETOLOGIA | 2024年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
74
引用
收藏
页码：S42 / S43
页数：2
相关论文
共 50 条
  • [21] A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects
    Zhou, Jie
    Cai, Xingguang
    Huang, Xun
    Dai, Yuxuan
    Sun, Lidan
    Zhang, Bo
    Yang, Bo
    Lin, Haiyan
    Huang, Wenlong
    Qian, Hai
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 138 : 1158 - 1169
  • [22] Exendin(9-39) is a partial agonist at the human glucagon-like peptide-1 receptor
    Kiel, D
    Lakis, JN
    May, JM
    DIABETES, 1999, 48 : A20 - A21
  • [23] Design and Development of a New Glucagon-Like Peptide-1 Receptor Agonist to Obtain High Oral Bioavailability
    Chen, Hao
    Lu, Yun
    Shi, Shuai
    Zhang, Qiang
    Cao, Xiaoli
    Sun, Lei
    An, Dong
    Zhang, Xiaojie
    Kong, Xianglin
    Liu, Jianping
    PHARMACEUTICAL RESEARCH, 2022, 39 (08) : 1891 - 1906
  • [24] Design and Development of a New Glucagon-Like Peptide-1 Receptor Agonist to Obtain High Oral Bioavailability
    Hao Chen
    Yun Lu
    Shuai Shi
    Qiang Zhang
    Xiaoli Cao
    Lei Sun
    Dong An
    Xiaojie Zhang
    Xianglin Kong
    Jianping Liu
    Pharmaceutical Research, 2022, 39 : 1891 - 1906
  • [25] Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study
    Takeshita, Yumie
    Kita, Yuki
    Tanaka, Takeo
    Goto, Hisanori
    Nakano, Yujiro
    Teramura, Chisato
    Enyama, Yasufumi
    Takamura, Toshinari
    JOURNAL OF DIABETES INVESTIGATION, 2022, 13 (06) : 965 - 974
  • [26] Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist
    Powell, Jason
    Piszczatoski, Chris
    Taylor, James R.
    CLINICAL THERAPEUTICS, 2020, 42 (10) : 2100 - 2116
  • [27] Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?
    Kim, Hwi Seung
    Jung, Chang Hee
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (18)
  • [28] Phase I Study of Glucagon-like Peptide-1/Glucagon Receptor Dual Agonist BI 456906 in Obesity
    Arrubla, Jorge
    Schoelch, Corinna
    Plum-Moerschel, Leona
    Kapitza, Christoph
    Lamers, Daniela
    Thamer, Claus
    Hennige, Anita M.
    OBESITY, 2021, 29 : 139 - 140
  • [29] Pharmacokinetics, pharmacodynamics and tolerability of single dose of recombinant glucagon-like peptide-1 receptor agonist in healthy Chinese subjects
    Lu, Min
    Zhu, Li-Xia
    Yan, Ji-Ling
    Wang, Ying-Zheng
    Zhao, Xia
    Zhou, Ying
    Cui, Yi-Min
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (05): : 8018 - 8024
  • [30] Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: Filling the gaps
    Dubin, Robert L.
    Heymsfield, Steven B.
    Ravussin, Eric
    Greenway, Frank L.
    DIABETES OBESITY & METABOLISM, 2024, 26 (12): : 5503 - 5518
12345